HeartBeam, Inc. (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses. The transaction, completed on April 16, 2026, was supported by key stakeholders including ClearCardio(TM), company leadership and institutional investors. The company plans to use the funds to accelerate commercialization of its FDA-cleared 12-lead synthesized ECG system, further develop its extended-wear patch and heart attack detection technologies, expand artificial intelligence capabilities, and for general corporate purposes.
HeartBeam is a medical technology company focused on transforming cardiac detection and monitoring. Its platform technology enables a cable-free device that collects ECG signals in 3D from three non-coplanar directions and synthesizes them into a 12-lead ECG. This innovation is designed for portable use, allowing physicians to identify cardiac health trends and acute conditions outside of medical facilities. The company’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software received clearance in December 2025. HeartBeam holds over 20 issued patents related to its technology.
The $10 million offering provides crucial capital to bring these technologies to market. The company’s FDA-cleared system could potentially redefine cardiac health management by enabling remote monitoring and early detection of heart attacks. With the additional funding, HeartBeam can expand its AI capabilities, which may enhance diagnostic accuracy and patient outcomes. The involvement of ClearCardio and institutional investors signals confidence in the technology’s commercial potential.
For more details, the full press release is available at https://ibn.fm/9iNYY. Further updates and news related to HeartBeam can be found in the company’s newsroom at https://ibn.fm/BEAT.
This development is significant for the medical technology sector as it underscores the growing investment in portable cardiac monitoring solutions. HeartBeam’s approach, which synthesizes a 12-lead ECG from a compact device, addresses a critical need for accessible cardiac care. The successful offering positions the company to compete in the remote cardiac monitoring market, potentially reducing hospital visits and enabling earlier intervention for heart conditions.
